ALFA Finder| Management target | Revenue 11.0% FY29 |
|---|
| Revenue growth | 8.2% YoY consolidated growth. |
|---|---|
| Margins | EBITDA margin 8.8%; targeting double-digit margins via cost optimization. |
| Order book | Excess of INR 250 crores in hand for Europe. |
| Demand visibility | Strong secondary demand in emerging markets; domestic seasonality impacted Q1. |
| Management confidence | High on domestic growth and efficiency measures. |
Growth
Consolidated revenue grew 8.2% YoY; domestic formulations grew 5.8% to INR 2,040 million; API business surged 42.4% YoY.
Outlook
Targeting double-digit EBITDA margins; plans to repay INR 260 Cr debt within 18 months; maintenance capex limited to INR 50 Cr.
Risks
Gross margins impacted by 200 bps due to raw material price hikes and war-related supply chain disruptions.
Last quarter's promises, checked
Delivered
- Guided US sterile sales from 2nd sites → Delivered 62.2% US growth (= BEAT)
- Guided 140 Cr debt repayment/year → Delivered 930 Cr debt from 960 Cr (= BEAT)
- Guided double-digit EBITDA margin → Delivered 10.9% consolidated (= BEAT)
Partly delivered
- Guided MMP efficiency gains → Delivered 26% fewer batches but margins still pressured (= PARTIAL)
Missed
- Guided India growth in line with IPM → Delivered 5.8% vs muted seasonality (= MISS)
Investor Presentation filed with BSE, NSE: INDOCO. Summary written with AI assistance from the document.
Indoco Remedies Ltd: key numbers
- Share price
- ₹228.65
- Market cap
- ₹2,111 Cr
- Revenue (annual)
- ₹1,845 Cr
- Net profit (annual)
- ₹-95.14 Cr
- P/E (TTM)
- 66.1×Sector 43.7×
- Promoter holding
- 58.92%+0.06% QoQ
- FII holding
- 1.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indoco Remedies Ltd
All →Indoco Remedies Promoter Buying: ₹0.12 Cr
Four Indoco Remedies promoters bought 5,225 shares on NSE on November 11 and 12, 2026. The purchases total about Rs.0.12 Crore, with each holding changing marginally.
- Value
- ₹0.12 Cr
Indoco Remedies Promoter Buying: ₹0.45 Cr
Four Indoco Remedies promoters bought 20,740 shares on NSE on 5 November 2026. Aggregate purchase value is about Rs.0.45 Crore.
- Value
- ₹0.45 Cr
Indoco Remedies Promoter Buying: ₹0.03 Cr
Indoco Remedies promoter and director Suresh G Kare bought 1,335 equity shares on the open market on 6 November 2026, raising holding from 1.42% to 1.42%. The trade value is Rs.2,84,248, about Rs.0.03 Crore.
- Value
- ₹0.03 Cr
Indoco Remedies Promoter Buying: ₹0.13 Cr
Indoco Remedies promoters Aditi M. Panandikar and Madhura Suresh Kare acquired a combined 5,996 equity shares via market purchase. The total transaction value is ₹0.13 Crore.
- Value
- ₹0.13 Cr
- Promoter stake change
- +0.01%
Indoco Remedies Promoter Buying: ₹0.17 Cr
Indoco Remedies' promoters Aditi Panandikar and Madhura Suresh Kare acquired 8,004 shares via market purchase. The total transaction value is ₹0.17 Crore.
- Value
- ₹0.17 Cr
Indoco Remedies Earnings Call Transcript: Key Takeaways
Indoco Remedies hit record quarterly revenue exceeding ₹500 Cr, but faced margin compression from elevated geopolitical freight and material costs.
- Call
- Guides 10% growth